Zimmer Biomet (NYSE:ZBH) Stock Rating Raised to “Hold” at Barclays

Barclays upgraded shares of Zimmer Biomet (NYSE:ZBH) to a hold rating in a research note issued to investors on Wednesday,Zacks reports.

A number of other equities research analysts also recently issued reports on ZBH. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Truist Financial raised their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada raised their price target on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $103.33.

Zimmer Biomet Stock Down 1.4%

Shares of ZBH opened at $88.42 on Wednesday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $106.88. The business’s 50 day moving average is $95.92 and its 200 day moving average is $91.12. The company has a market capitalization of $16.86 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 1.69 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts expect that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of ZBH. BlackRock Inc. purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth $1,344,282,000. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet in the second quarter valued at about $328,578,000. Bank of America Corp DE acquired a new stake in Zimmer Biomet during the second quarter worth about $187,480,000. Auto Owners Insurance Co raised its stake in Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after purchasing an additional 1,987,362 shares during the period. Finally, Equity Investment Corp purchased a new position in Zimmer Biomet during the second quarter worth about $144,748,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.